These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23847360)

  • 1. Entinostat plus exemestane has activity in ER+ advanced breast cancer.
    Cancer Discov; 2013 Jul; 3(7):OF17. PubMed ID: 23847360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
    Connolly RM; Zhao F; Miller KD; Lee MJ; Piekarz RL; Smith KL; Brown-Glaberman UA; Winn JS; Faller BA; Onitilo AA; Burkard ME; Budd GT; Levine EG; Royce ME; Kaufman PA; Thomas A; Trepel JB; Wolff AC; Sparano JA
    J Clin Oncol; 2021 Oct; 39(28):3171-3181. PubMed ID: 34357781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
    Yardley DA; Ismail-Khan RR; Melichar B; Lichinitser M; Munster PN; Klein PM; Cruickshank S; Miller KD; Lee MJ; Trepel JB
    J Clin Oncol; 2013 Jun; 31(17):2128-35. PubMed ID: 23650416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
    Masuda N; Tamura K; Yasojima H; Shimomura A; Sawaki M; Lee MJ; Yuno A; Trepel J; Kimura R; Nishimura Y; Saji S; Iwata H
    BMC Cancer; 2021 Nov; 21(1):1269. PubMed ID: 34819039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
    Baselga J; Morales SM; Awada A; Blum JL; Tan AR; Ewertz M; Cortes J; Moy B; Ruddy KJ; Haddad T; Ciruelos EM; Vuylsteke P; Ebbinghaus S; Im E; Eaton L; Pathiraja K; Gause C; Mauro D; Jones MB; Rugo HS
    Breast Cancer Res Treat; 2017 Jun; 163(3):535-544. PubMed ID: 28324268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entinostat: a promising treatment option for patients with advanced breast cancer.
    Connolly RM; Rudek MA; Piekarz R
    Future Oncol; 2017 Jun; 13(13):1137-1148. PubMed ID: 28326839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib ups PFS in HER2-/ER+ breast cancer.
    Cancer Discov; 2014 Jun; 4(6):624-5. PubMed ID: 24891344
    [No Abstract]   [Full Text] [Related]  

  • 10. [Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
    Ito Y; Masuda N; Iwata H; Mukai H; Horiguchi J; Tokuda Y; Kuroi K; Mori A; Ohno N; Noguchi S
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):67-75. PubMed ID: 25596682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
    Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
    Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palbociclib improves survival in advanced breast cancer.
    Burki TK
    Lancet Oncol; 2017 Jan; 18(1):e1. PubMed ID: 27890465
    [No Abstract]   [Full Text] [Related]  

  • 13. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 15. Exemestane and chemotherapy as first-line treatment of metastatic breast cancer: results of a phase II study.
    de la Haba-Rodriguez J; Mancha RG; Manga GP; Aguilar EA; Baena Cañada JM; Rovira PS; Conejo EA
    Clin Breast Cancer; 2010 Aug; 10(4):313-7. PubMed ID: 20705565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
    Love RR; Hutson PR; Havighurst TC; Cleary JF
    Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
    Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
    Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
    van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
    Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
    N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.
    Ibrahim NK; Yariz KO; Bondarenko I; Manikhas A; Semiglazov V; Alyasova A; Komisarenko V; Shparyk Y; Murray JL; Jones D; Senderovich S; Chau A; Erlandsson F; Acton G; Pegram M
    Clin Cancer Res; 2011 Nov; 17(21):6822-30. PubMed ID: 21878535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.